N4 PHARMA PLC

Report Publication Announcement • Feb 7, 2025

National Storage Mechanism | Additional information

RNS Number : 2346W

N4 Pharma PLC

07 February 2025

7 February 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

Investor Webinar

N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases , is pleased to announce   that   Nigel Theobald, Chief Executive Officer will be presenting at the ShareSoc Discovery Company Webinar on  Tuesday, 25 February 2025 at 5.00 pm.

Further details of the event and registration form are available here:

https://www.sharesoc.org/events/discovery-company-webinar-25-february-25/

- Ends -

For more information please contact:

N4 Pharma plc Nigel Theobald, Chief Executive Officer Luke Cairns, Executive Director	Via N4 Pharma Investor Hub Sign up at investors.n4pharma.com
Investor questions on this announcement We also invite investors to ask questions on this announcement via our investor hub	https://investors.n4pharma.com/link/0rJx8y
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: +44 (0) 20 3470 0470
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/James Pope	Tel: +44 (0) 20 3657 0050
Northstar Communications Limited Investor Relations Sarah Hollins	Tel: +44 (0) 113 730 3896

About N4 Pharma

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases .

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn's disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments.  

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEASAKEEPSEFA